U.S. markets open in 2 hours 52 minutes
  • S&P Futures

    3,861.50
    +42.25 (+1.11%)
     
  • Dow Futures

    31,959.00
    +183.00 (+0.58%)
     
  • Nasdaq Futures

    12,591.25
    +294.00 (+2.39%)
     
  • Russell 2000 Futures

    2,235.80
    +35.00 (+1.59%)
     
  • Crude Oil

    65.70
    +0.65 (+1.00%)
     
  • Gold

    1,704.70
    +26.70 (+1.59%)
     
  • Silver

    25.88
    +0.61 (+2.40%)
     
  • EUR/USD

    1.1913
    +0.0061 (+0.51%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • Vix

    24.38
    -0.28 (-1.14%)
     
  • GBP/USD

    1.3883
    +0.0062 (+0.45%)
     
  • USD/JPY

    108.6900
    -0.2110 (-0.19%)
     
  • BTC-USD

    53,997.86
    +3,838.76 (+7.65%)
     
  • CMC Crypto 200

    1,089.82
    +65.61 (+6.41%)
     
  • FTSE 100

    6,777.57
    +58.44 (+0.87%)
     
  • Nikkei 225

    29,027.94
    +284.69 (+0.99%)
     

Kala Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2020 financial results on Thursday, May 7, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.

The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 9468562. To access a live webcast and subsequent archived recording of the call, please visit the "Investors & Media" section on the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFYTM mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the January 2019 launch of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% and its investigational product candidate, EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25%, which is being studied for the short-term treatment of the signs and symptoms of dry eye disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200430005092/en/

Contacts

Investor Contact:
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200